JNJ/PTGX: JNJ2113: Oral dosing faces hurdles of new rival classes in psoriasis & Ulcerative Colitis
The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory...
top of page
Recent Research
Jun 12, 2023
MRK/MRNA: ASCO: vaccine-PD1 similar to historic PD1 alone
New data from MRK/MRNA cancer vaccine at ASCO last week continues to suggest a large underperformance of Keytruda control arm, along with...
Jun 6, 2023
NOVN: NATALEE's Kisqali of Life
As we highlighted in our February 23, 2020 report “Kisqali’s kiss of life“, NOVN's NATALEE trial of Kisqali demonstrated the broadest...
May 28, 2023
Still no light from TIGIT trials at ASCO23
While ASCO 2023 does not offer much in updates for the three current lead contenders for anti-TIGIT combinations in non-small cell lung canc
Apr 18, 2023
mRNA-PD1 cancer vaccine trial control arm may have underperformed
In newly published data from Merck /Moderna’s PD1 + mRNA cancer vaccine trial, efficacy may be flattered by Keytruda alone control arm under
Mar 20, 2023
Little hope in TIGIT trials to date
As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients.
The failure of Merck’s TIGIT+PD1 combo to beat second line
Feb 23, 2023
PFE: ACIP: Prevnar protects against some new but not all old infections
New data from Pfizer’s pneumococcal vaccine reveals inferiority to an important serotype 3 that makes up approximately one third of cases
Dec 21, 2022
PFE pipeline Swim in a big pond if you're 2nd to jump in
We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a
Aug 28, 2022
BMY/JNJ/BAY: Milvexian moves ahead at ESC
The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...
Aug 14, 2022
Roche: Maintaining Leadership is difficult: nearterm pipeline outlook
We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page